PT - JOURNAL ARTICLE AU - Romano-Keeler, Joann AU - Fiszbein, Dana AU - Zhang, Jilei AU - Horowitz, Joseph AU - Hayani, Karen AU - Buhimschi, Irina AU - Lopez, Christina AU - Kadhem, Zaynab AU - Berman, James AU - Rasamimari, Phornphat AU - Raghavan, Aarti AU - Pillers, De-Ann M. AU - Sun, Jun TI - Center-Based Experiences Implementing Strategies to Reduce Risk of Horizontal Transmission of SARS-Cov-2: Potential for Compromise of Neonatal Microbiome Assemblage AID - 10.1101/2021.01.07.21249418 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.07.21249418 4099 - http://medrxiv.org/content/early/2021/01/08/2021.01.07.21249418.1.short 4100 - http://medrxiv.org/content/early/2021/01/08/2021.01.07.21249418.1.full AB - Perinatal transmission of COVID-19 is poorly understood and many neonatal intensive care units’ (NICU) policies minimize mother-infant contact to prevent transmission. We present our unit’s approach and ways it may impact neonatal microbiome acquisition. We attended COVID-19 positive mothers’ deliveries from March-August 2020. Delayed cord clamping and skin-to-skin were avoided and infants were admitted to the NICU. No parents’ visits were allowed and discharge was arranged with COVID-19 negative family members. Maternal breast milk was restricted in the NICU. All twenty-one infants tested negative at 24 and 48 hours and had average hospital stays of nine days. 40% of mothers expressed breastmilk and 60% of infants were discharged with COVID-19 negative caregivers. Extended hospital stays, no skin-to-skin contact, limited maternal milk use, and discharge to caregivers outside primary residences, potentially affect the neonatal microbiome. Future studies are warranted to explore how ours and other centers’ similar policies influence this outcome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Jun Sun receives funding from NIDDK/National Institutes of Health grants NIDDKR01 DK105118 and R01DK114126.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Illinois at Chicago Institutional Review Board (protocol no. 2020-0443).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data pertaining to this manuscript are stored on Box.com through a University Box Health Data Folder, which is a HIPAA compliant tool for secure storage of Protected Health Information.